** Shares of drugmaker ImmunityBio IBRX.O rise 11.1% to $2.3
** Co posts Q1 revenue of $16.5 million, beating analysts' average estimate of $16.02 million, according to data compiled by LSEG
** IBRX reports Q1 net loss of 15 cents/share vs analysts' est of 13 cents/share
** Including session's moves, IBRX stock down 10.7% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.